These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 20479080)
1. Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity. Veesenmeyer JL; Howell H; Halavaty AS; Ahrens S; Anderson WF; Hauser AR Infect Immun; 2010 Aug; 78(8):3346-57. PubMed ID: 20479080 [TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644 [TBL] [Abstract][Full Text] [Related]
3. Mutation of the phospholipase catalytic domain of the Pseudomonas aeruginosa cytotoxin ExoU abolishes colonization promoting activity and reduces corneal disease severity. Tam C; Lewis SE; Li WY; Lee E; Evans DJ; Fleiszig SM Exp Eye Res; 2007 Dec; 85(6):799-805. PubMed ID: 17905228 [TBL] [Abstract][Full Text] [Related]
4. A novel phosphatidylinositol 4,5-bisphosphate binding domain mediates plasma membrane localization of ExoU and other patatin-like phospholipases. Tyson GH; Halavaty AS; Kim H; Geissler B; Agard M; Satchell KJ; Cho W; Anderson WF; Hauser AR J Biol Chem; 2015 Jan; 290(5):2919-37. PubMed ID: 25505182 [TBL] [Abstract][Full Text] [Related]
5. Activation of ExoU phospholipase activity requires specific C-terminal regions. Schmalzer KM; Benson MA; Frank DW J Bacteriol; 2010 Apr; 192(7):1801-12. PubMed ID: 20097856 [TBL] [Abstract][Full Text] [Related]
6. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. Howell HA; Logan LK; Hauser AR mBio; 2013 Mar; 4(2):e00032-13. PubMed ID: 23481600 [TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU. Zhang A; Veesenmeyer JL; Hauser AR Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456 [TBL] [Abstract][Full Text] [Related]
8. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU. Rabin SD; Hauser AR Infect Immun; 2005 Jan; 73(1):573-82. PubMed ID: 15618197 [TBL] [Abstract][Full Text] [Related]
9. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Allewelt M; Coleman FT; Grout M; Priebe GP; Pier GB Infect Immun; 2000 Jul; 68(7):3998-4004. PubMed ID: 10858214 [TBL] [Abstract][Full Text] [Related]
10. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Rabin SD; Veesenmeyer JL; Bieging KT; Hauser AR Infect Immun; 2006 May; 74(5):2552-61. PubMed ID: 16622190 [TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa toxin ExoU induces a PAF-dependent impairment of alveolar fibrin turnover secondary to enhanced activation of coagulation and increased expression of plasminogen activator inhibitor-1 in the course of mice pneumosepsis. Machado GB; de Oliveira AV; Saliba AM; de Lima CD; Suassuna JH; Plotkowski MC Respir Res; 2011 Aug; 12(1):104. PubMed ID: 21819560 [TBL] [Abstract][Full Text] [Related]
13. Presence of the exoU gene of Pseudomonas aeruginosa is correlated with cytotoxicity in MDCK cells but not with colonization in BALB/c mice. Lin HH; Huang SP; Teng HC; Ji DD; Chen YS; Chen YL J Clin Microbiol; 2006 Dec; 44(12):4596-7. PubMed ID: 17050810 [TBL] [Abstract][Full Text] [Related]
14. ExoU is a potent intracellular phospholipase. Sato H; Frank DW Mol Microbiol; 2004 Sep; 53(5):1279-90. PubMed ID: 15387809 [TBL] [Abstract][Full Text] [Related]
15. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496 [TBL] [Abstract][Full Text] [Related]
16. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Sato H; Feix JB; Frank DW Biochemistry; 2006 Aug; 45(34):10368-75. PubMed ID: 16922513 [TBL] [Abstract][Full Text] [Related]
17. Induced conformational changes in the activation of the Pseudomonas aeruginosa type III toxin, ExoU. Benson MA; Komas SM; Schmalzer KM; Casey MS; Frank DW; Feix JB Biophys J; 2011 Mar; 100(5):1335-43. PubMed ID: 21354407 [TBL] [Abstract][Full Text] [Related]
18. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. Schulert GS; Feltman H; Rabin SD; Martin CG; Battle SE; Rello J; Hauser AR J Infect Dis; 2003 Dec; 188(11):1695-706. PubMed ID: 14639541 [TBL] [Abstract][Full Text] [Related]
19. Effector ExoU from the type III secretion system is an important modulator of gene expression in lung epithelial cells in response to Pseudomonas aeruginosa infection. McMorran B; Town L; Costelloe E; Palmer J; Engel J; Hume D; Wainwright B Infect Immun; 2003 Oct; 71(10):6035-44. PubMed ID: 14500525 [TBL] [Abstract][Full Text] [Related]
20. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Lee VT; Smith RS; Tümmler B; Lory S Infect Immun; 2005 Mar; 73(3):1695-705. PubMed ID: 15731070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]